The effect of fucoxanthin on the development of CCl4-induced liver fibrosis
Open Access
- 29 June 2023
- journal article
- research article
- Published by Kemerovo State Medical University in Fundamental and Clinical Medicine
- Vol. 8 (2) , 8-18
Abstract
Background. According to current concepts regarding hepatic fibrosis, myofibroblast differentiation from stellate cells, regulated by transforming growth factor-β (TGF-β), is a key step in its pathogenesis. Hence, inhibition of TGF-β-dependent activation of hepatic stellate cells has been suggested as a promising strategy for preventing the disease development.Aim. To explore whether the administration of fucoxanthin at a dose of 30 mg/kg is efficient in suppressing hepatic fibrosis.Materials and Methods. The experiments were carried out on 30 outbred ICR/CD1 mice which have been divided into three groups: intact animals, animals with untreated hepatic fibrosis which has been induced by intraperitoneal injections of CCl4 (2 μl/g, 6 weeks, twice per week), and animals which received fucoxanthin per os (30 mg/kg daily for 5 weeks) after inducing hepatic fibrosis as described above. Histological examination was performed by Sirius Red staining using the METAVIR fibrosis and activity score. Immunohistochemical analysis was performed by quantitation of α-SMA-positive myofibroblasts, CD45-positive leukocytes, and TIMP-1-positive regions. Further, we quantified TGF-β in liver homogenate as well as interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in the serum by means of enzyme-linked immunosorbent assay. An assessment of liver function was conducted by measuring serum alanine aminotransferase, aspartate aminotransferase, and albumin levels.Results. Fucoxanthin decreased the number of myofibroblasts and leukocytes, the volume of connective tissue and TIMP-1-positive regions, and the level of TGF-β in the liver homogenate, altogether indicative of ameliorated hepatic fibrosis. In accord, treatment with fucoxanthin reduced serum IL-1β, TNF-α, alanine aminotransferase and aspartate aminotransferase, and increased serum albumin.Conclusion. Treatment with fucoxanthin at a dose of 30 mg/kg has an antifibrotic effect and diminishes liver fibrosis.Keywords
This publication has 23 references indexed in Scilit:
- First Evidence for the Anti-inflammatory Activity of Fucoxanthin in High-Fat-Diet-Induced Obesity in Mice and the Antioxidant Functions in PC12 CellsInflammation, 2013
- Hepatic Stellate Cells and Liver Fibrosis2013
- Origins and functions of liver myofibroblastsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
- Inactivation of myofibroblasts during regression of liver fibrosisCell Cycle, 2013
- Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidasesKidney International, 2011
- Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-κB and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophagesEuropean Journal of Pharmacology, 2010
- Bioavailability and metabolism of fucoxanthin in rats: structural characterization of metabolites by LC-MS (APCI)Molecular and Cellular Biochemistry, 2009
- TGF-β and fibrosis in different organs — molecular pathway imprintsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Grading and staging systems for inflammation and fibrosis in chronic liver diseasesJournal of Hepatology, 2007
- Effects of fucoxanthin on lipopolysaccharide-induced inflammation in vitro and in vivoExperimental Eye Research, 2005